NCT05896254View on ClinicalTrials.gov

Study of MAR001 in Adults With Metabolic Dysfunction

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

55

Participants

Timeline

Start Date

July 22, 2023

Primary Completion Date

December 13, 2024

Study Completion Date

December 13, 2024

Conditions

Hypertriglyceridemia

Interventions

DRUG

MAR001

Subcutaneous injection

DRUG

Placebo

Subcutaneous injection

Trial Locations (2)

3004

Melbourne Site, Melbourne

4006

Brisbane Site, Brisbane

Sponsors

Lead Sponsor

Marea Therapeutics

All Listed Sponsors

lead

Marea Therapeutics

INDUSTRY

NCT05896254 - Study of MAR001 in Adults With Metabolic Dysfunction | Biotech Hunter | Biotech Hunter